Alpha-Mannosidosis – Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 4 PAGES: 30

Alpha-Mannosidosis – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Alpha-Mannosidosis - Pipeline Review, H2 2011', provides an overview of the Alpha-Mannosidosis therapeutic pipeline. This report provides information on the therapeutic development for Alpha-Mannosidosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alpha-Mannosidosis. 'Alpha-Mannosidosis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Alpha-Mannosidosis.
- A review of the Alpha-Mannosidosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Alpha-Mannosidosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Alpha-Mannosidosis.
- Identify emerging players with potentially strong product portfolio and desig

More Info
									Alpha-Mannosidosis – Pipeline Review, H2 2011




           Alpha-Mannosidosis – Pipeline Review, H2 2011


                                                                                          Reference Code: GMDHC1608IDB
                                                                                          Publication Date: December 2011




Alpha-Mannosidosis – Pipeline Review, H2 2011                                             GMDHC1608IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Alpha-Mannosidosis – Pipeline Review, H2 2011




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 3
    List of Figures ................................................................................................................................................................................ 3
Introduction......................................................................................................................................................................................... 4
    Global Markets Direct Report Coverage ........................................................................................................................................ 4
Alpha-Mannosidosis Overview ........................................................................................................................................................... 5
Therapeutics Development................................................................................................................................................................. 6
    An Overview of Pipeline Products for Alpha-Mannosidosis ........................................................................................................... 6
Alpha-Mannosidosis Therapeutics under Development by Companies ............................................................................................. 8
Alpha-Mannosidosis Therapeutics under Investigation by Universities/Institutes ............................................................................... 9
Mid Clinical Stage Products.............................................................................................................................................................. 10
    Comparative Analysis .................................................................................................................................................................. 10
Alpha-Mannosidosis Therapeutics – Products under Development by Companies ......................................................................... 11
Alpha-Mannosidosis Therapeutics – Products under Investigation by Universities/Institutes ........................................................... 12
Companies Involved in Alpha-Mannosidosis Therapeutics Development ........................................................................................ 13
    Zymenex A/S ............................................................................................................................................................................... 13
Alpha-Mannosidosis – Therapeutics Assessment ............................................................................................................................ 14
    Assessment by Monotherapy Products ....................................................................................................................................... 14
    Assessment by Combination Products ........................................................................................................................................ 15
    Assessment by Route of Administration ...................................................................................................................................... 16
    Assessment by Molecule Type .................................................................................................................................................... 18
Drug Profiles..................................................................................................................................................................................... 20
    Lamazym - Drug Profile ............................................................................................................................................................... 20
         Product Description................................................................................................................................................................. 20
         Mechanism of Action ............................................................................................................................................................... 20
         R&D Progress ......................................................................................................................................................................... 20
    Campath-1H + Cyclophosphamide + Busulfan + Allogeneic Stem Cell Transplantation - Drug Profile ....................................... 21
         Product Description................................................................................................................................................................. 21
         Mechanism of Action ............................................................................................................................................................... 21
         R&D Progress ......................................................................................................................................................................... 21
    Busulfan + Cyclophosphamide + Antithymocyte Globulin + Hematopoietic Stem Cell Transplantation - Drug Profile ................ 23
         Product Description................................................................................................................................................................. 23
         Mechanism of Action .......
								
To top